Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095065
Filing Date
2024-08-12
Accepted
2024-08-12 07:20:41
Documents
56
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q prld-20240630.htm   iXBRL 10-Q 1545425
2 EX-31.1 prld-ex31_1.htm EX-31.1 15941
3 EX-31.2 prld-ex31_2.htm EX-31.2 15951
4 EX-32.1 prld-ex32_1.htm EX-32.1 8659
5 EX-32.2 prld-ex32_2.htm EX-32.2 8792
  Complete submission text file 0000950170-24-095065.txt   7035817

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240630.xsd EX-101.SCH 1072324
58 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240630_htm.xml XML 1313194
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39527 | Film No.: 241194737
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)